tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Assembly Biosciences Reports Interim Results for ABI-6250

Story Highlights
  • Assembly Biosciences announced interim results for ABI-6250 and positive data for ABI-4334.
  • The company reported a net loss of $10.2 million in Q2 2025, with operations funded into mid-2026.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
Assembly Biosciences Reports Interim Results for ABI-6250

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

An update from Assembly Biosciences ( (ASMB) ) is now available.

On August 6, 2025, Assembly Biosciences announced interim results from their Phase 1a clinical study of ABI-6250, a candidate for treating hepatitis delta virus (HDV). The company reported positive topline data from a Phase 1b study of ABI-4334 for chronic hepatitis B virus (HBV) and shared updates on their ongoing trials for herpes simplex virus (HSV) candidates ABI-5366 and ABI-1179. Financially, Assembly Biosciences reported a net loss of $10.2 million for the second quarter of 2025, with cash reserves projected to fund operations into mid-2026. The company continues to advance its clinical programs, aiming to deliver impactful datasets for its development candidates by the end of the year.

The most recent analyst rating on (ASMB) stock is a Buy with a $29.00 price target. To see the full list of analyst forecasts on Assembly Biosciences stock, see the ASMB Stock Forecast page.

Spark’s Take on ASMB Stock

According to Spark, TipRanks’ AI Analyst, ASMB is a Neutral.

The overall score reflects significant financial challenges, with the company’s lack of revenue and negative cash flows weighing heavily. However, positive technical momentum and a recent successful clinical trial offer potential upside. Valuation metrics remain weak due to negative earnings, highlighting risk for investors.

To see Spark’s full report on ASMB stock, click here.

More about Assembly Biosciences

Assembly Biosciences is a biotechnology company dedicated to developing innovative small-molecule therapeutics aimed at altering the course of serious viral diseases, including herpesvirus, hepatitis B virus (HBV), and hepatitis delta virus (HDV) infections. The company is led by a team of experts in virologic drug development and is focused on improving patient outcomes worldwide.

Average Trading Volume: 29,071

Technical Sentiment Signal: Hold

Current Market Cap: $144M

See more insights into ASMB stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1